44 clinical trials found.
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
The purpose of the study is to determine and evaluate the safety, tolerability, and preliminary efficacy of oral LY3537982 as monotherapy and as part of ...Phase
TRIAL ROLE: Principal Investigator
-
An open label Phase I dose escalation trial with dose confirmation and expansion of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
In the first part of the study, we will test the safety, tolerance, and how the body processes a drug called BI 1810631 in patients ...
Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase ...Phase
TRIAL ROLE: Sub Investigator
-
Phase II: Adaptive De-escalation of Radiation Therapy Dose In Favorable Risk HPV-Positive Oropharyngeal Carcinoma (ART)
The main goal of this study is to determine if deescalating chemoradiation treatment based on early tumor shrinkage at mid-treatment can result in similar cancer ...
Phase
TRIAL ROLE: Sub Investigator
-
A Modular Open-label Phase I/II Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
RET alterations mostly happen in lung cancer and thyroid cancer, these alterations can be picked up on molecular testing and can be a target for ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination with a PARP Inhibitor in Patients with BRCA 1/2 Mutant or Other HRD+ Advanced or Metastatic S
This study is split into two parts: Phase 1 and Phase 2. The study team is testing a new medicine, TNG348, for patients with tumors ...
Phase
TRIAL ROLE: Sub Investigator
-
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
A study called TNG462-C101 is being conducted to test a new medicine called TNG462 on patients with advanced or metastatic solid tumors who have a ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
This study is being conducted to determine how safe and effective a drug called DZD9008 is compared to standard chemotherapy in patients with locally advanced ...Phase
TRIAL ROLE: Sub Investigator
